Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma. (Q55073624)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

author name string

A Grey

1

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

A Cooper

2

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

C McNeil

3

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

S O'Toole

4

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

J Thompson

5

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

P Grimison

6

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

publication date

1 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

Internal Medicine Journal

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

44

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

6

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

597-600

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

BRAF signaling and targeted therapies in melanoma

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

BRAF as therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

Melanoma--an unlikely poster child for personalized cancer therapy.

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

Progression of RAS-mutant leukemia during RAF inhibitor treatment

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

Ras oncogenes: split personalities

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

High-throughput oncogene mutation profiling in human cancer

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.12415

21 January 2018

Identifiers

10.1111/IMJ.12415

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 June 2018

http://europepmc.org/abstract/MED/24946815

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55073624&oldid=1525679795"